Clinical outcomes and germline implications of primary KIT exon 13 and 17 mutations in gastrointestinal stromal tumors
Authors:
- 21 October 2026
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 29 (6) , 1258-1267
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2020
- Multiple gastrointestinal stromal tumors caused by a novel germline KIT gene mutation (Asp820Gly): a case report and literature reviewGastric Cancer, 2020
- Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experienceCancer Medicine, 2019
- Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13European Journal of Cancer, 2013
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Gastrointestinal stromal tumours: origin and molecular oncologyNature Reviews Cancer, 2011
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEuropean Journal of Cancer, 2006
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal of Cancer, 2004